EUCTR2018-003707-19-IT进行中（未招募）1 期
A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First line Platinum Based Chemotherapy - .
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- MERCK KGAA
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are = 18 years of age at the time of signing the informed consent. In Japan, if a participant is at least 18 but < 20 years of age, written informed consent from his/her parent or guardian will be required in addition to the participant’s written consent.
- •2. Are participants with histologically or cytologically confirmed locally advanced or metastatic BTC.
- •3. Availability of tumor (primary or metastatic) archival material or fresh biopsies (collected within 28 days before first administration of study intervention) is mandatory. Fine needle aspirates, transductal aspirates, or cell blocks are not acceptable. Endoscopic retrograde cholangiography or intraductal ultrasounds assisted biopsy is acceptable, needle or excisional biopsies, or resected tissue, are preferable. Tumor biopsies and tumor archival material must be suitable for biomarker assessment as described in the Laboratory Manual.
- •4. Participants with BTC must have failed or be intolerant to 1L systemic platinum-based chemotherapy. Participants who received adjuvant platinum-based chemotherapy and had evidence of disease recurrence within 6 months of completion of the adjuvant treatment are also eligible. If recurrence occurs during or within 6 months after the adjuvant chemotherapy, adjuvant platinum-based chemotherapy is counted as 1L chemotherapy.
- •5. Disease must be measurable with at least 1 unidimensionally measurable lesion by RECIST 1.1 and verified independently by an Independent Review Committee (IRC).
- •6. Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1 at study entry and Day 1 of treatment with M7824.
- •7. Life expectancy = 12 weeks as judged by the Investigator.
- •9. Adequate hematological function defined by white blood cell (WBC) count = 3 × 109/L with absolute neutrophil count (ANC) = 1.5 × 109/L, lymphocyte count = 0.5 × 109/L, platelet count = 75 × 109/L, and hemoglobin (Hgb) = 9 g/dL (in absence of blood transfusion).
- •10. Adequate hepatic function defined by a total bilirubin level = 1.5 × upper limit of normal (ULN), an aspartate aminotransferase (AST) level = 2.5 × ULN, and an alanine aminotransferase (ALT) level = 2.5 × ULN. For participants with liver involvement in their tumor, AST = 5.0 × ULN and ALT = 5.0 × ULN is acceptable.
- •11. Adequate coagulation function defined as prothrombin time (PT) or international normalized ratio (INR) = 1.5 × ULN unless the participant is receiving anticoagulant therapy.
- •12. Albumin = 3.0 g/dL.
- •13. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive participants must be treated and on a stable dose of antivirals (e.g., entecavir, tenofovir, or lamivudine; adefovir or interferon are not allowed) at study entry and with planned monitoring and management including baseline HBV DNA quantity according to appropriate labeling guidance. Participants receiving active hepatitis C virus (HCV) therapy must be on a stable dose at study entry and with planned monitoring and management according to appropriate labeling guidance of an approved antiviral.
- •For other criteria refer to the Protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 85
排除标准
- •1. Ampullary cancer is excluded.
- •2. Rapid clinical deterioration other than malignancy which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or study procedures.
- •3. Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention are excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.
- •5.Other previous and/or intercurrent malignancy except for curatively treated cancers with no recurrence in > 3 years since treatment completion, or
- •early cancers treated with curative intent, including cervical carcinoma in situ, superficial, noninvasive bladder cancer, or basal cell or squamous cell
- •carcinoma in situ. Endoscopically resected early gastrointestinal cancers limited in mucosal layer (esophageal, gastric, and colorectal) that are without
- •recurrence in > 1 year are allowed.
- •6. Significant acute or chronic infections, including:
- •Uncontrolled biliary infection. Biliary tract obstruction should be released by stenting or percutaneous transhepatic biliary drainage
- •Known history of positive test for HIV or known acquired immunodeficiency syndrome.
- •Active tuberculosis infection (clinical symptoms, physical or radiographic, and laboratory findings)
- •Active bacterial or fungal infection requiring IV systemic therapy (except as indicated, discuss alternative scenarios with the Medical Monitor).
- •7. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:
- •Participants with diabetes type 1, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
- •Participants requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses = 10 mg of prednisone or equivalent per day
- •Administration of steroids for other conditions through a route known to result in a minimal systemic exposure is acceptable.
- •8.History of non-infectious ILD requiring systemic steroid treatment, or current pneumonitis
- •9. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before enrollment.
- •10. Known severe hypersensitivity (Grade = 3 National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 [NCI CTCAE 5.0]) to investigational product (M7824) or any components in their formulations, any history of anaphylaxis, or recent, within 5 months, history of uncontrolled asthma.
- •11. Persisting Grade > 1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade = 2 is acceptable.
- •12. Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia.
- •For other criteria refer to Clinical Trial Protocol
研究者
相似试验
进行中（未招募）
1 期
Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum Based ChemotherapyEUCTR2018-003707-19-GBMerck KGaA141
进行中（未招募）
1 期
Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum Based ChemotherapyEUCTR2018-003707-19-FRMerck KGaA141
进行中（未招募）
1 期
Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum Based ChemotherapyBiliary Tract CancerMedDRA version: 20.0Level: LLTClassification code 10028982Term: Neoplasm biliary tractSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074879Term: Extrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003707-19-DEMerck KGaA141
进行中（未招募）
1 期
Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum Based ChemotherapyBiliary Tract CancerMedDRA version: 20.0 Level: LLT Classification code 10028982 Term: Neoplasm biliary tract System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10073077 Term: Intrahepatic cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10074879 Term: Extrahepatic cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10017614 Term: Gallbladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003707-19-ESMerck KGaA141
已完成
2 期
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)Biliary Tract CancerJPRN-jRCT2080224605Merck Biopharma Co., Ltd. Japan141